Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval Strategic partnership with Biocodex in biotherapeutics ...
Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is currently the most advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback